Ticagrelor in patients with acute coronary syndrome

Česká verzia

Authors: J. Špinar; J. Vítovec
Published in the journal: Kardiol Rev Int Med 2012, 14(3): 194-199
Category:

Summary

Ticagrelor is an oral, reversible, direct inhibitor of the P2Y₁₂ type adenosine diphosphate (ADP) receptor characterised by a faster onset of action and by a more expressed antiaggregatory activity compared to clopidogrel, and it does not belong to the thienopyridine group. In the major PLATO multicentre study (180 mg loading dose, 90 mg b.i.d.) ticagrelor was tested against clopidogrel (300–600 mg loading dose, 75 mg daily) in 18,624 patients suffering from acute coronary syndrome with and without ST elevation. After 12 months, the composite of CV death, myocardial infarction and cerebrovascular accident had occurred in 9.8% of ticagrelor--treated patients versus 11.7% of clopidogrel-treated patients (p < 0.001). No difference was observed in the occurrence of severe bleeding (11.6% vs. 11.2%, p = 0.43). In December 2010, ticagrelor was also registered in the Czech Republic, under the Brilique trademark; since June 2012 it has been covered by health insurance and some centres already have initial clinical experience with it.

Keywords:
ticagrelor – acute coronary syndrome – dual antiaggregation – mortality – bleeding

Zdroje

1. Bultas J. Tikagrelor. Remedia 2011; 21: 116–125.

2. Penka M. Antikoagulační a antiagregační léčba – základní principy. Kardiol Rev 2012; 14: 63–67.

3. Penka M. Máme dnes lepší antitrombotika? Kardiol Rev 2012; 14: 62.

4. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–1057.

5. Špinar J, Vítovec J. Komu zvoní hrana. Kardiol Rev 2009; 11: 197–199.

6. Špinar J, Vítovec J. Studie RE-LY a PLATO – budeme přepisovat guidelines. Bulletin Hypertenze 2010; 13: 22–25.

7. Scirica BM, Vannon CHP, Emanuelsson H et al. The incidence or arrhytmias and clinical arrhytmias events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO trial. JACC 2010; 55 (10A): 1100–1274.

8. Storey RF, Bliden KP, Patil SB et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. J Am Coll Cardiol 2010; 56: 185–193.

9. U.S. Food and Drug Administration. BrilintaTM Prescribin Information. http://www.accessdata.fda.gov/drugsatda/label/2011/022433s000lbl.pdf.

10. Štípal R. Perorální protidestičková léčba u pacientů s akutním koronárním syndromem. Kardiol Rev 2012; 14: 68–71.